IDEAYA Biosciences

US · IDYA #2357 by market cap Listed 2019

35.56 -0.70 -1.93%

Live - 5344 symbols - heartbeat 544s ago · 2026-10-08 09:58

Pre-market 35.83 -1.19%

After-hours 36.26 0.00%

Market cap: 3.43B
P/E (TTM): -18.52
P/B: 2.86
EPS: -1.28
Div yield: 0.00%
52W pos: 57%

Reader sentiment Are you bullish or bearish on IDYA?

Anonymous reader poll. Unscientific, not investment advice.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Founded: 2015
CEO: Mr. Yujiro S. Hata
Employees: 145
Headquarters: South San Francisco, California, United States of America
Fiscal year end: 12-31
Website: ideayabio.com

Company profile

Exchange: US
Symbol: IDYA
Market-cap rank: #2357
Listing date: 2019-05-23
Market cap: 3.43B
Float cap: 3.22B
Shares out: 96.49M
Float shares: 90.63M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 09:58:55 · For reference only, not investment advice and not tailored to your situation.